“Australia’s Psychedelic Drug Trial”
The Saturday Paper discusses Australia’s first approved psilocybin clinical trial exploring psilocybin as a treatment for anxiety in the terminally ill. Sponsored by the Australian nonprofit Psychedelic Research in Science and Medicine (PRISM) and to be conducted at Melbourne’s St. Vincent’s Hospital, the cGMP psilocybin used for this trial will be donated by Usona Institute.
The Saturday Paper.
“Psychedelic Mushrooms Are Closer to Medicinal Use (It’s Not Just Your Imagination)”
The New York Times discusses how shifts in cultural perspectives and advancements in research may lead to psilocybin’s eventual use as a legal medicine. New York Times.
“Life, death and psychedelic drugs”
CNN reports on the therapeutic effects of MDMA (for PTSD) and psilocybin (for end-of-life anxiety) on study participants. CNN.
“Altered States of Mental Health Treatment”
Usona collaborators Paul Hutson, PhD and Christopher Nicholas, PhD discuss past and upcoming psilocybin and MDMA studies at the University of Wisconsin-Madison School of Pharmacy. UW-Madison School of Pharmacy.
“Michael Pollan on testing psychedelics as a treatment for depression”
Michael Pollan and CBS news anchors discuss the potential of psychedelics to treat a variety of psychological conditions, including depression. CBS News.
“The New Science of Psychedelics”
Michael Pollan discusses the history of psychedelic research, as well as contemporary studies examining psilocybin for the alleviation of depression, anxiety, and addiction. The Wall Street Journal.
“Running Away or Righting Away: Is Psilocybin a Viable Psychiatric Treatment?”
Charles Raison MD and Michael Bogenschutz MD discuss the history and potential of psilocybin research. MD Magazine
“Magic Mushrooms ‘reboot’ brain in depressed people – study”
Research at Imperial College London suggests that psilocybin may help to “reboot” neural circuits in those experiencing treatment-resistant depression. The Guardian
“Decoding the Tripping Brain”
How progress in research is shedding light onto the underlying mechanisms behind the therapeutic effects of psychedelics, including anti-depressive and anti-inflammatory properties. The Scientist
“Why psychedelic drugs are having a medical renaissance”
Video segment on MDMA and psilocybin-based therapies. PBS Newshour
Johns Hopkins and NYU studies in psilocybin as a treatment for cancer-related psychological distress. Two clinical studies (released Dec. 1, 2016) examining the effect of psilocybin on symptoms of depression and anxiety in people with life-threatening cancer were released and covered by a number of media. News outlets included CNN, New York Times, Newsweek, PBS Newshour, Science, Scientific American, The Atlantic, The Guardian, Time, and USA Today, among others.
“Hallucinogen Therapy is Coming”
How psilocybin treatment can spring people from fears and destructive habits. Nautilus
“The fascinating, strange medical potential of psychedelic drugs, explained in 50+ studies”
Show Me the Evidence staff examines more than 50 studies analyzing the safety and efficacy of psychedelic drugs and psychedelic-assisted therapy and interviews researchers involved in the work. Vox
“Magic-mushroom drug lifts depression in first human trial”
Imperial College study provides preliminary support for the safety and efficacy of psilocybin as a therapy for treatment-resistant depression. Nature
“Psilocybin can reduce the pain of social exclusion”
Researchers at the University of Zurich show that a small amount of psilocybin can reduce the distress caused by mild social exclusion and lessens activity in the area of the brain associated with this emotion. Newsweek
“Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA”
Drug-assisted psychotherapy as a possible alternative to existing pharmacological and psychological treatments. The Lancet Psychiatry
“Can Mushrooms Treat Depression?”
One woman’s intimate tale of her experience with plant based medicines. The New York Times
“The Trip Treatment”
Research into psychedelics, shut down for decades, is now yielding results. The New Yorker
“Why Doctors Die Differently”
Research shows the attributes of a “good death” are hard to find. Wall Street Journal
“How Psychedelic Drugs Can Help Patients Face Death”
Experience of patients with advanced cancer in psilocybin study. New York Times Magazine
“Professor Probes Psychedelic Drugs for a Cure to Nicotine Addiction”
Recent John’s Hopkins study on effecting addictive behavior with psychedelics. Washingtonian
“Neurons to Nirvana”
A 2013 Documentary Trailer (YouTube)
“Meditation and Psychedelics”
Article written for Multidisciplinary Association for Psychedelic Studies (MAPS) by Zen Priest, Vanja Palmer, Co-Founder of the House of Silence in Austria and Felsetnor in Switzerland. Multidisciplinary Association for Psychedelic Studies (MAPS)